Business Context and Reporting Period
This Form 8-K Current Report was filed by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) on February 5, 2024. The report discloses material events occurring in late January 2024, specifically the acquisition of intellectual property rights and the engagement of an investor relations firm.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figures disclosed relate to the consideration for a new asset purchase agreement:
- Upfront Payment: $10,000 per inventor (total $20,000) upon signing.
- Milestone Payments: $10,000 per inventor upon receipt of an NIH research grant or completion of an IND validation study.
- Regulatory Milestone: $30,000 per inventor upon receipt of IND approval.
- Royalties: 3.0% of net cash revenues from the invention (1.5% per inventor) upon commercialization.
Material Changes
The primary material change reported is the entry into a definitive agreement on January 30, 2024, to acquire the "PSMA-Boron" invention. This asset is designed as a theranostic agent for the diagnosis, staging, and therapy of prostate cancers. The agreement assigns all rights, title, and interest in the invention to the Company from inventors Alan Kozikowksi and Werner Tueckmantel. Additionally, on January 22, 2024, the Company engaged John Columbia Inc. to provide enhanced investor relations services alongside its existing firm, Lytham Partners, LLC.
Outlook, Risks, and Contingencies
Management expects to use the PSMA-Boron invention to identify sites of metastatic cancer deposits to direct radiation therapy, contingent upon successful validation studies and FDA approvals. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks and uncertainties. No specific financial guidance or outlook for the fiscal year was provided in this report.
Investor Verification Checklist
- Verify the status of the "PSMA-Boron" invention and any prior assignments by Dr. Anatoly Dritschilo.
- Confirm the Company's current cash position to ensure it can fund the upfront and potential milestone payments.
- Review the Company's pipeline for existing NIH grant applications related to this invention.
- Assess the timeline for the required validation studies and IND filing.
- Monitor the scope of services provided by the newly engaged investor relations firm, John Columbia Inc.